Ultra Market Research | Global Psoriasis Biosimilars Market
Global Psoriasis Biosimilars Market
Report ID : 822
Category : Pharmaceuticals,Healthcare-Services
No Of Pages : 130
Published on: November 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
Introduction Global Psoriasis Biosimilars Market refers to the growing segment of pharmaceutical biosimilars specifically designed for the treatment of psoriasis, a chronic inflammatory skin condition characterized by red, itchy, and scaly patches. Biosimilars are biologic drugs highly similar to approved biologics but typically offered at a lower cost, making them an attractive option for healthcare systems and patients seeking effective psoriasis treatments. Recent advancements in biotechnology and the expiry of patents for branded biologics are driving growth in the psoriasis biosimilars market. Furthermore, the rising prevalence of psoriasis and greater acceptance of biosimilars globally contribute to expanding demand and application. The industry is seeing significant research and development in biosimilars that promise higher efficacy and safety, coupled with increased regulatory support in various regions to improve accessibility.
Amgen Inc. (USA) Pfizer Inc. (USA) Novartis International AG (Switzerland) Samsung Bioepis Co., Ltd. (South Korea) Mylan N.V. (USA) Celltrion Healthcare (South Korea) Biocon Limited (India) Sandoz International GmbH (Germany) Stada Arzneimittel AG (Germany) Coherus BioSciences, Inc. (USA) Boehringer Ingelheim (Germany) Dr. Reddy's Laboratories (India) Hetero Drugs Ltd. (India) Alvotech (Iceland) Fresenius Kabi AG (Germany)
Drivers
The primary factors driving growth in the Psoriasis Biosimilars Market include the increasing prevalence of psoriasis and the rising demand for affordable treatments. Globally, millions of people suffer from psoriasis, and the demand for effective treatment options continues to grow. Biosimilars provide a cost-effective alternative to biologics, making them attractive to both patients and healthcare providers. Regulatory agencies worldwide are actively encouraging biosimilars to enter the market by providing streamlined approval processes, further enhancing growth prospects. Additionally, the expiration of patents on several branded biologics has opened the market for biosimilars, giving companies an opportunity to introduce new products with comparable efficacy. These combined factors underscore the demand for psoriasis biosimilars and continue to propel the market forward.
Restraints
Despite its promising outlook, the psoriasis biosimilars market faces several challenges. One of the primary obstacles is the complexity and cost associated with the manufacturing of biosimilars, which requires advanced technology and stringent quality control. This often results in significant capital investment, which can deter new players. Additionally, healthcare providers and patients may have lingering concerns over the efficacy and safety of biosimilars compared to branded biologics. Brand loyalty and the influence of established pharmaceutical companies may also limit the market share of biosimilars. Furthermore, strict regulatory guidelines, particularly in North America and Europe, pose significant barriers that companies must navigate to gain market approval, adding further cost and time constraint
Opportunity
The growing acceptance of biosimilars in both developed and emerging markets presents substantial opportunities in the Psoriasis Biosimilars Market. Rising healthcare expenditures, particularly in developing countries, encourage governments and insurers to support biosimilars as a cost-effective solution for chronic conditions like psoriasis. In response, major players are expanding their geographic footprint to cater to these high-potential regions. Moreover, ongoing advancements in biosimilar technology are making it possible to develop biosimilars that closely mimic branded biologics in terms of efficacy and safety, which is likely to increase acceptance among healthcare providers. Collaborations between biotech firms and pharmaceutical companies are also helping to drive innovation, further supporting market growth.
Trend
One of the latest trends in the Psoriasis Biosimilars Market is the focus on personalized medicine. Companies are investing in research to better understand individual responses to psoriasis treatments, paving the way for biosimilars tailored to specific patient profiles. Additionally, there is a growing emphasis on self-administered biosimilars, particularly with the rise of subcutaneous injection options, allowing patients to manage their condition more conveniently at home. Digital health technologies are also influencing this market, with several companies exploring partnerships with tech firms to provide apps that help patients track treatment effectiveness and manage their medication schedules. This trend reflects a broader shift toward patient-centered care within the biosimilars landscape.
Key Target Audience
Pharmaceutical companies Biosimilar manufacturers Healthcare providers Research and development organizations Regulatory authorities Hospitals and clinics Distributors and suppliers Investors and financial analysts
Psoriasis biosimilars are biologic drugs designed to closely resemble original biologics for treating psoriasis but are generally more affordable.
The rising prevalence of psoriasis, patent expirations of branded biologics, and demand for affordable treatment options are key drivers.
Biosimilars undergo rigorous regulatory processes to ensure they match the safety, efficacy, and quality of the original biologic, varying by country.
North America, Europe, and parts of Asia-Pacific are key regions due to high prevalence and supportive regulations for biosimilars.
The market is expected to grow steadily due to increased patient demand, government support, and advancements in biosimilar manufacturing technology.
Table of Contents Executive Summary 1.1 Overview of the Psoriasis Biosimilars Market 1.2 Key Findings 1.3 Market Trends and Insights 1.4 Strategic Recommendations
Introduction 2.1 Background and Context 2.2 Scope of the Study 2.3 Market Definition and Segmentation 2.4 Research Methodology 2.5 Data Sources
Market Dynamics 3.1 Market Drivers 3.1.1 Growing Prevalence of Psoriasis 3.1.2 Cost-Effectiveness of Biosimilars 3.1.3 Advances in Biotechnology 3.2 Market Restraints 3.2.1 Regulatory Challenges 3.2.2 Safety Concerns and Market Acceptance 3.3 Market Opportunities 3.3.1 Expansion in Emerging Markets 3.3.2 Partnerships and Collaborations 3.4 Market Trends 3.4.1 Personalized Treatment Approaches 3.4.2 Adoption of Biologics and Biosimilars in Dermatology 3.5 Impact of COVID-19 on the Market
Global Market Overview 4.1 Market Size and Forecast 4.2 Market Share Analysis 4.3 Regional Market Overview 4.3.1 North America 4.3.2 Europe 4.3.3 Asia-Pacific 4.3.4 Latin America 4.3.5 Middle East & Africa
Market Segmentation 5.1 By Product Type 5.1.1 Tumor Necrosis Factor (TNF) Inhibitors 5.1.2 Interleukin Inhibitors 5.1.3 Other Biosimilars 5.2 By Route of Administration 5.2.1 Injectable 5.2.2 Oral 5.3 By Distribution Channel 5.3.1 Hospital Pharmacies 5.3.2 Retail Pharmacies 5.3.3 Online Pharmacies
Competitive Landscape 6.1 Key Market Players 6.2 Market Share Analysis of Leading Players 6.3 Strategic Initiatives by Key Players 6.4 Recent Developments in the Market 6.4.1 Product Launches 6.4.2 Mergers and Acquisitions 6.4.3 Partnerships and Collaborations
Regulatory Landscape 7.1 Regulatory Guidelines for Biosimilars 7.2 Approval Process in Major Markets 7.3 Impact of Regulatory Challenges on Market Growth
Technological Advancements 8.1 Innovations in Biosimilar Development 8.2 Impact of Technology on Market Competitiveness 8.3 Future Trends in Psoriasis Treatment
Market Outlook and Future Trends 9.1 Growth Projections for the Psoriasis Biosimilars Market 9.2 Future Opportunities and Risks 9.3 Strategic Recommendations for Market Players
Appendices 10.1 List of Abbreviations 10.2 Industry Acronyms 10.3 References
List of Tables Table 1: Global Psoriasis Biosimilars Market Size and Forecast (2024-2030) Table 2: Market Share of Psoriasis Biosimilars by Region (2024) Table 3: Psoriasis Biosimilars Market by Product Type (2024) Table 4: Competitive Landscape – Key Players and Market Share Table 5: Market Size and Growth Rate by Route of Administration (2024-2030) Table 6: Key Regulatory Guidelines for Biosimilars in Major Markets Table 7: Strategic Initiatives and Recent Developments by Key Market Players Table 8: Technological Innovations in Psoriasis Biosimilars Development Table 9: Global Growth Opportunities for Psoriasis Biosimilars (2024-2030) Table 10: Psoriasis Biosimilars Market Risks and Strategic Recommendations
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings Internal and external proprietary databases, relevant patent and regulatory databases National government documents, statistical databases and market reports News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process Middle Circle Represents – Source of Information Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc. Helps in validating and strengthening the secondary research findings Further develops the analysis team’s expertise and market understanding Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers Purchasing managers, technical personnel, distributors and resellers Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment Macro-economic indicators: GDP, etc. Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities. Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps:
2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of Human Osteoblasts Marketand its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of Human Osteoblasts Marketfor the past year and forecasts for the next six years .Human Osteoblasts Marketsize is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different Human Osteoblasts Marketcategories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for Human Osteoblasts Market from different application industries in different regions.
